Start Date
June 1, 2025
Primary Completion Date
December 31, 2025
Study Completion Date
June 30, 2026
inhaled nitric oxide (iNO)
"Inhaled nitric oxide (iNO), which is known mainly from the pulmonary hypertension literature for its therapeutic role in pulmonary arterial hypertension, has been proposed as a potential pharmacologic adjunct to standard anticoagulation in acute PE.~Inhaled nitric oxide (iNO) will be administered at 30 ppm for 3 minutes. The measurements will be obtained/calculated before, during iNO administration, and after iNO has been withheld for 2 minutes."
Ronald Reagan UCLA Medical Center, Los Angeles
Collaborators (1)
Mallinckrodt
INDUSTRY
University of California, Los Angeles
OTHER